Skip to content

MDMA: all studies

Page 237 of 346: studies 2,361 to 2,370 of 3,454, newest first. Back to the MDMA overview

Research

Legal highs: staying on top of the flood of novel psychoactive substances

Therapeutic Advances in Psychopharmacology January 26, 2015 David Baumeister, Luis M. Tojo, Derek K. Tracy 158 citations

There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon...

"Addicted to Euphoria": The History, Clinical Presentation, and Management of Party Drug Misuse.

International review of neurobiology 2015 Jenny Bearn, Matthew O'Brien

Eating, drinking, sexual activity, and parenting invoke pleasure, an emotion that promotes repetition of these behaviors, are essential for survival. Euphoria, a feeling or state of intense excitement and happiness, is an amplification of pleasure, aspired to one's essential biological needs that are satisfied. People use party drugs as a shortcut to euphoria. Ecstasy...

Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions

BioMed Research International 2015 Débora González, Marta Torrens, Magı́ Farré 44 citations

Background . 2C-B (Nexus) is one of the most widespread novel psychoactive substances. There is limited information about its pharmacological properties, and few studies in humans concern its acute and chronic effects. 2C-B has been classified as a stimulant, hallucinogen, entactogen, and/or empathogen. Objectives . To evaluate the emotional, subjective, and cardiovascular effects of 2C-B....

Recreational Use, Analysis and Toxicity of Tryptamines

Current Neuropharmacology December 10, 2014 Roberta Tittarelli, Giulio Mannocchi, Flaminia Pantano et al. 217 citations

Information from Internet and from published scientific literature, organized in the way we proposed in this review, provides an effective tool for specialists facing the emerging NPS threat to public health and public security, including the personnel working in Emergency Department.

Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines

Journal of Neuroscience November 12, 2014 Michael H. Baumann, Ernesto Solis, Lucas R. Watterson et al. 157 citations

The abuse of synthetic psychoactive substances known as "designer drugs," or "new psychoactive substances" (NPS), is increasing at an alarming rate. NPS are purchased as alternatives to traditional illicit drugs of abuse and are manufactured to circumvent laws regulating the sale and use of controlled substances. Synthetic cathinones (i.e., "bath salts") and synthetic cannabinoids (i.e.,...

DOI: 10.1523/jneurosci.3223-14.2014 (opens in new tab) Full text (opens in new tab) MDMA Synthetic cannabinoids Designer drug Recreational drug +4

Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3′,4′‐methylenedioxy‐4‐methylaminorex (MDMAR)

Drug Testing and Analysis October 20, 2014 Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh et al. 18 citations

The recent occurrence of deaths associated with the psychostimulant cis-4,4'-dimethylaminorex (4,4'-DMAR) in Europe indicated the presence of a newly emerged psychoactive substance on the market. Subsequently, the existence of 3,4-methylenedioxy-4-methylaminorex (MDMAR) has come to the authors' attention and this study describes the synthesis of cis- and trans-MDMAR followed by extensive...

Awash in a sea of ‘bath salts’: implications for biomedical research and public health

Addiction July 1, 2014 Michael H. Baumann 49 citations

The emergence of ‘bath salts’ products containing synthetic cathinones represents a global public health threat. Synthetic cathinones have significant abuse potential, and the effects of high-dose administration can be life-threatening. More preclinical and human research is needed to understand the complex pharmacology and toxicology of these substances. During the past several years, there...

Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).

Journal of Psychopharmacology March 27, 2014 Alfred Richard Green, David Nutt

Despite the publication of a substantial body of preclinical and clinical information on recent recreational drugs such as 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and cathinone compounds such as mephedrone there remains a disturbing lack of consensus as to how dangerous these compounds are to the health of the individual and to society in general. This perspective proposes that use...

The preclinical pharmacology of mephedrone; not justMDMAby another name

British Journal of Pharmacology March 24, 2014 Andrew R. Green, Madeleine V. King, Sinead E Shortall et al. 70 citations

The substituted β‐keto amphetamine mephedrone (4‐methylmethcathinone) was banned in the UK in A pril 2010 but continues to be used recreationally in the UK and elsewhere. Users have compared its psychoactive effects to those of 3,4‐methylenedioxymethamphetamine ( MDMA , ‘ecstasy’). This review critically examines the preclinical data on mephedrone that have appeared over the last 2–3 years and,...

Drug Abuse and Cardiac Problem

Medicine Today February 10, 2014 Mohammad Shafiqur Rahman Patwary, Kazi Abdullah Al Mamun 4 citations

Drug abuse has reached epidemic proportions in many countries including Bangladesh and threatens to overwhelm economic, social, and health care systems. In addition to their effects on the central nervous system, many of these agents induce profound changes in the heart and circulation that are responsible for a significant proportion of drug-related morbidity. Drugs that can affect the...